T. Hurst

发表

Increased expression of the nme1 gene is associated with metastasis in epithelial ovarian cancer

G. Chenevix-Trench, C. Houghton, J. Leary, 1995, International journal of cancer.

In vitro sensitivity of ovarian cancer as determined by a short-term biochemical assay: comparison between primary and metastatic sites in the same patient.

M. J. Webb, P. Parsons, E. Mackay, 1989, Gynecologic oncology.

Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy.

J. Dickinson, P. Parsons, Y. Dong, 1997, Biochemical pharmacology.

Sporadic Tumors

G. Chenevix-Trench, J. Leary, T. Hurst, 2007 .

Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus.

G. Chenevix-Trench, M. Friedlander, J. Leary, 1996, Oncogene.

Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations

A. Shelling, G. Chenevix-Trench, J. Barrett, 1997, Genes, chromosomes & cancer.

Effect of interferon γ and tumour necrosis factor α on sensitivity to cisplatin in ovarian carcinoma cell lines

M. McGuckin, T. Hurst, B. Ward, 1994, Cancer Immunology, Immunotherapy.

Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.

Michael D. Bailey, M. McGuckin, T. Hurst, 1990 .

Predictive value of serial CA 125 antigen levels in ovarian cancer evaluated by second-look laparotomy.

M. J. Webb, J. Kearsley, E. Mackay, 1987, European journal of cancer & clinical oncology.

Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma

M. McGuckin, T. Hurst, B. Ward, 1995, International journal of cancer.

CYP 17 PROMOTOR POLYMORPHISM AND OVARIAN CANCER RISK

A. Spurdle, G. Chenevix-Trench, Xiaoqing Chen, 2000 .

EFFECT OF INTERFERON-y AND TNF-a ON MUCl MUCIN EXPRESSION IN OVARIAN CARCINOMA CELL LINES

M. McGuckin, T. Hurst, S. Clark, 2014 .

Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.

P. Parsons, T. Hurst, E. Kable, 1990, Biochemical pharmacology.

The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer

D. Battistutta, T. Hurst, S. Khoo, 1993, Cancer.

Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.

P. Parsons, T. Hurst, S. Khoo, 1992, International journal of cell cloning.

Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas

G. Chenevix-Trench, J. Kerr, T. Hurst, 1998, Oncogene.

Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours

G. Chenevix-Trench, B. Wainwright, J. Kerr, 1997, International journal of cancer.

Effect of interferon-gamma and TNF-alpha on MUC1 mucin expression in ovarian carcinoma cell lines.

M. McGuckin, T. Hurst, B. Ward, 1994, Disease markers.

Expression of Multiple Tumour Markers in Serum from Patients with Ovarian Carcinoma and Healthy Women

M. McGuckin, T. Hurst, S. Khoo, 1989, The Australian & New Zealand journal of obstetrics & gynaecology.

Prognostic significance of tumor ploidy in patients with advanced ovarian carcinoma

J. Kearsley, T. Hurst, S. Khoo, 1990, Gynecologic oncology.

Increased expression of cyclin‐dependent kinase inhibitor 2 (CDKN2A) gene product P16 INK4A in ovarian cancer is associated with progression and unfavourable prognosis

M. Cummings, P. Parsons, M. McGuckin, 1997, International journal of cancer.

Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer

M. Cummings, P. Parsons, B. Gabrielli, 1997, International journal of cancer.

Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.

G. Chenevix-Trench, M. Friedlander, J. Leary, 1994, American journal of human genetics.

Chemosensitivity Testing of Ovarian Cancer: Results of a Rapid in Vitro Biochemical Assay

M. J. Webb, T. Hurst, S. Khoo, 1985, The Australian & New Zealand journal of obstetrics & gynaecology.

Detection of somatic DNA alterations in ovarian cancer by DNA fingerprint analysis

T. Hurst, S. Khoo, Philip Chen, 1991, Cancer.

Cisplatin Chemotherapy of Ovarian Cancer: Is Short‐Term In Vitro Chemosensitivity Predictive of Long‐Term Patient Survival?

M. J. Webb, P. Parsons, J. Kearsley, 1988, The Australian & New Zealand journal of obstetrics & gynaecology.

Short‐Term In Vitro Chemosensitivity Testing of Tumours of the Ovary, Cervix and Uterus, Measurement of DNA Metabolism by H Thymidine Incorporation

M. J. Webb, E. Mackay, T. Hurst, 1986, The Australian & New Zealand journal of obstetrics & gynaecology.

No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasms.

G. Chenevix-Trench, J. Kerr, T. Hurst, 1998, Gynecologic oncology.

Measurement of tumor cell activity in short‐term primary culture. Clinical significance in women with ovarian cancer

M. J. Webb, P. Parsons, J. Kearsley, 1988, Cancer.

Clinical value of in vitro drug sensitivity testing based on short‐term effects on dna and rna metabolism in ovarian cancer

M. J. Webb, P. Parsons, J. Kearsley, 1989, Journal of surgical oncology.

Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.

G. Chenevix-Trench, M. Friedlander, R. Kefford, 1992, Oncogene.

β‐Catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours

G. Chenevix-Trench, M. Cummings, I. Campbell, 1999, International journal of cancer.

CYP17 promotor polymorphism and ovarian cancer risk

A. Spurdle, G. Chenevix-Trench, Xiaoqing Chen, 2000, International journal of cancer.

Evaluation of two new assays for tumor‐associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma — Comparison with CA125

T. Hurst, M. McGuckin, Bg Ward, 1991, Gynecologic oncology.